TABLE 2.
Outcomes at 6 months, observed values (n = 28) and after imputations for missing values (n = 30)
| Needle type | |||
| Umbrella-shaped (N = 25) | Single needle (N = 5) | Total (N = 30) | |
| Primary outcome | |||
| n successb/N total (%) [95% CI] | 13/24 (54.2%) [32.8–74.4%] | 1/4 (25.0%) [0.6–80.6%] | 14/28 (50.0%) [30.6–69.4%] |
| n successb/N totala (%) [95% CI] | 13/25 (52.0%) [31.3–72.2%] | 1/5 (20.0%) [0.5–71.6%] | 14/30 (46.7%) [28.3–65.7%] |
| Secondary outcomes | |||
| Potassium ≥3.6 mmol/l without potassium supplementation, n (%) [95% CI] | 18/21 (85.7%) [63.7–97.0%] | 0/2 (0%) [0–84.2%] | 18/23 (78.3%) [56.3–92.5%] |
| Potassium ≥3.6 mmol/l without potassium supplementationa, n (%) [95% CI] | 21/25 (84.0%) [63.9–95.5%] | 0/5 (0%) [0–52.2%] | 21/30 (70.0%) [50.6–85.3%] |
| Normalized aldosterone-to-renin ratio, n (%) [95% CI] | 19/19 (100%) [82.4–100%] | 0/2 (0%) [0–84.2%] | 19/21 (90.5%) [69.6–98.8%] |
| Normalized aldosterone-to-renin ratioa, n (%) [95% CI] | 23/25 (92.0%) [74.0–99.0%] | 0/5 (0%) [0–52.2%] | 23/30 (76.7%) [57.7–90.1%] |
CI, confidence interval.
a
After imputation of missing outcomes.
b
Successes are defined as daytime SBP/DBP less than 135/85 mmHg at 6 months measured by ABPM without antihypertensive treatment or a decrease in daytime SBP of 20 mmHg or of DBP of 10 mmHg between baseline and 6 months.